Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein – a generic to Lucentis – for clinical trials

Celon Pharma S.A. concluded an agreement with Biotechpharma on industrial development of the anti-VEGF protein – a generic to Lucentis (ranibizumab) in line with GMP for the purpose of clinical trials. The positive results of the work we carried out so far as well as over PLN 24 million of co-funding from the National CentreRead more »

Aleksandra Stańczak at the Cancer Molecular Biology in Clinical Practice

Aleksandra Stańczak, PhD, Leader of the Oncology Research Team took part in the 7th edition of the conference: “Cancer Molecular Biology in Clinical Practice”, which was held at the end of November 2017 in Warsaw. At the: conference Ms Stańczak presented the most important assumptions of the project:  CELONKO – Development of modern biomarkers andRead more »

Conclusion of the decentralised marketing authorisation procedure for Salmex in Scandinavian countries

The procedure included: Sweden, Finland, Norway, Denmark and Iceland. The Company’s business partner in the scope of obtaining marketing authorisation and product distribution in the markets covered by the DCP is Glenmark. The countries covered by the Scandinavian procedure have issued positive decisions on acceptance of the submitted marketing authorisation dossier. Bogdan Manowski, Director forRead more »